AEZS - Aeterna Zentaris Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8000
-0.0800 (-2.78%)
At close: 03:58PM EDT
Stock chart is not supported by your current browser
Previous Close2.8800
Open2.7800
Bid2.4200 x 1100
Ask3.1900 x 1000
Day's Range2.7800 - 2.8899
52 Week Range2.3200 - 8.7500
Volume4,990
Avg. Volume15,835
Market Cap13.596M
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-4.8800
Earnings DateAug 01, 2023 - Aug 07, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders

    TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that its Virtual Annual General and Special Meeting of Shareholders (the “AGM”) will be held on June 14, 2023, at 10:00 a.m. (ET). The platform for the virtual AGM will provide shareholders the ability to listen to the

  • GlobeNewswire

    Aeterna Zentaris Reports First Quarter 2023 Financial Results

    – Ended the quarter with $46.6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerate recruitment for DETECT trial Actively seeking alternate development and commercialization partners for Macrilen® (macimorelin) in the U.S. and other territories not currently partnered TORONTO, ONTARIO, May 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializ

  • Zacks

    Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug

    Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.

  • Baystreet

    Stocks in play: AEterna Zentaris Inc

    Announced that sales of Macrilen® will be temporarily discontinued in the United States commercial market ...

  • GlobeNewswire

    Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial

    U.S. sales of Macrilen® for adult use to be temporarily discontinued as of May 23, 2023, while DETECT trial continues in order to expand the opportunity for pediatric usage of Macrilen®Sales and commercialization efforts continue to move forward in European Economic Area and UK under recent agreement with PharmanoviaUnited States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Aeterna’s U.S. patent application related to use of macimorelin for Assessing Growth Hormone

  • Zacks

    Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

    Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

    – Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025– Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go decision milestones – Ongoing efforts to accelerate recruitment for our DETECT trial and establish partnering rights to Macrilen™ in the U.S. and Canada TORONTO, ONTARIO, March 23, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)

  • GlobeNewswire

    Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)

    Pharmanovia to acquire license to GHRYVELIN™ from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO, ONTARIO, March 16, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Pharmanovia, a global lifecycle management healthcare company, has acquired from th

  • Zacks

    Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?

    Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.

  • Zacks

    Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

    Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

  • GlobeNewswire

    Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

    Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development pipeline, advancing towards go/no-go decision milestones at each stage to establish prioritization and drive momentumStrategic decision to streamline development programs by discontinuing the Company’s early-stage vaccine programs provides Aeterna Zentaris with an expected extended cas

  • ACCESSWIRE

    JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

    JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.

  • GlobeNewswire

    Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

    Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 1

  • Zacks

    Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates

    Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Aeterna Zentaris Reports Third Quarter 2022 Financial Results

    – Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the third quarter ended Sept

  • GlobeNewswire

    Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

    – Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 study “DETECT-trial" of macimorelin for the diagnosis of childhood-onset growth hormone deficiency (CGHD) TORONTO, ON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing the

  • GlobeNewswire

    Aeterna Zentaris Reports Second Quarter 2022 Financial Results and Recent Highlights

    – Company ended the quarter with $58.2 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the second quarter ended Jun

  • Zacks

    CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Aeterna Zentaris Announces Effective Date of Share Consolidation

    TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has filed articles of amendment, to effect the previously announced share consolidation (or reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one post-Consolidati

  • GlobeNewswire

    Aeterna Zentaris Announces Shareholder Approval of Share Consolidation

    TORONTO, ONTARIO, July 15, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the proposed consolidation of the Company’s shares (the “Share Consolidation”) was approved at its reconvened annual meeting of shareholders (the “Meeting”) held today. Following the Meeting, the Company’s board

  • GlobeNewswire

    Aeterna Zentaris Announces Further Adjournment of Shareholder Meeting

    TORONTO, ONTARIO, July 06, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that the Company has further adjourned its annual general and special meeting of shareholders (the "Meeting"). The Meeting was originally held on June 21, 2022, and was reconvened and further adjourned today prior to

  • GlobeNewswire

    Aeterna Zentaris Announces Results of Annual Meeting of Shareholders

    - Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all items of business, other than the proposed consolidation of the Company's shares (the "Share Consolidation"), were approved at its annual meetin

  • GlobeNewswire

    Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program

    – Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD") – Positive results presented at the 13th International Congress on Autoimmunity being held in Athens, Greece – Preliminary data with mouse 2D2 models of spontaneous autoimmune encephalomyelitis (EAE) indicate that mouse-adapted AIM Biologicals may reduce optic neuritis, loss of inner nuclear layer neurons and EAE symptoms TORONTO, ONTARIO, June

  • GlobeNewswire

    Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference

    Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 12:3

  • Simply Wall St.

    Here's Why We're Watching Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...